Abstract
Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have